Skip to main content

Table 2 Tumor characteristics at diagnosis according to mammographic density at diagnosis

From: Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

  BI-RADSa aBI-RADS bBI-RADS cBI-RADS d
Estrogen receptor statuspositive5 (31.3)69 (57.5)89 (63.6)20 (76.9)
negative11 (68.8)47 (39.2)46 (32.9)6 (23.1)
missing 4 (3.3)5 (3.6) 
Progesterone receptor statuspositive4 (25.0)44 (36.7)77 (55.0)15 (57.7)
negative12 (75.0)72 (60.0)58 (41.4)11 (42.3)
missing 4 (3.3)5 (3.6) 
HER2 statuspositive3 (18.8)45 (37.5)38 (27.1)9 (34.6)
negative11 (68.8)68 (56.7)95 (67.9)17 (65.4)
missing2 (12.5)7 (5.8)7 (5.0) 
Ki67> 20% (high)12 (75.0)89 (74.2)89 (63.6)15 (57.7)
<=20% (low)2 (12.5)9 (7.5)25 (17.9)3 (11.5)
missing2 (12.5)22 (18.3)26 (18.6)8 (30.8)
FNAb axillapositive FNA11 (68.8)80 (66.7)91 (65.0)15 (57.7)
negative FNA 8 (6.7)10 (7.1)4 (15.4)
inconclusive FNA1 (6.3) 3 (2.1)1 (3.8)
no FNA4 (25.0)32 (26.7)35 (25.0)6 (23.1)
missing  1 (0.7) 
Tumor size at diagnosis (mm)cmedian (IQR)34 (23–40)30 (21–40)35 (25–50)30 (20–40)
  1. aThroughout the table BI-RADS breast composition is intended
  2. bfine needle aspiration
  3. cMeasured in mammograms or in ultrasound images. When both methods were conclusive an average measure was used